0001429560
false
0001429560
2023-08-14
2023-08-14
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
August 14, 2023
TREVENA, INC.
(Exact name of registrant as specified in
its charter)
Delaware
(State or other jurisdiction of incorporation)
001-36193 |
|
26-1469215 |
(Commission File No.) |
|
(IRS Employer Identification No.) |
955 Chesterbrook Boulevard, Suite 110
Chesterbrook, PA 19087
(Address of principal executive offices and zip
code)
Registrant’s telephone number, including
area code: (610) 354-8840
Not applicable
(Former name or former address, if changed
since last report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section
12(b) of the Act:
Title of each class | |
Trading Symbol(s) | |
Name of each exchange on which registered |
Common Stock, $0.001 par value | |
TRVN | |
The Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company
¨
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
| Item 2.02. | Results of Operations and Financial Condition. |
On August 14, 2023, Trevena, Inc. (the “Company”) issued
a press release announcing its financial results and other business updates for the quarter ended June 30, 2023. A copy of the press release
is furnished hereto as Exhibit 99.1 and incorporated herein by reference.
The information under this caption and contained in the press release
attached hereto as Exhibit 99.1 is furnished by the Company in accordance with Securities Exchange Commission Release No. 33-8216. This
information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the
“Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange
Act whether made before or after the date of this Current Report, except as shall be expressly set forth by specific reference in such
a filing.
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
TREVENA, INC. |
|
|
Date: August 14, 2023 |
By: |
/s/ Barry Shin |
|
|
Barry Shin |
|
|
Senior Vice President & Chief Financial Officer |
Exhibit 99.1
Trevena Reports
Second Quarter 2023 Results and Provides Business Update
Company announces
database lock for TRV045 proof-of-concept TMS study evaluating potential for use in epilepsy; topline data expected 3Q 2023
TRV045 proof-of-concept
study evaluating potential for use in acute and chronic pain advancing with topline data expected 3Q 2023
New respiratory
data from VOLITION ~200 patient real-world outcomes study, using continuous respiratory monitoring, expected 3Q 2023
Company previously
announced results of ARTEMIS study in which OLINVYK-treated patients had a statistically significant ~$8,750 (19%) lower cost per admission
and ~1.4 day (20%) reduced average length of hospital stay, compared to matched patients treated with other IV opioids
Company previously
announced $3 million milestone payment from Jiangsu Nhwa Pharmaceutical; anticipates receipt of additional $15 million non-dilutive tranche
from R-Bridge 3Q 2023
CHESTERBROOK, Pa., August 14, 2023 (GLOBE
NEWSWIRE) –Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel
medicines for patients with central nervous system (CNS) disorders, today reported its financial results for the second quarter ended
June 30, 2023 and provided an overview of its recent operational highlights.
“This is an exciting time for
Trevena as we near completion of proof-of-concept studies evaluating the potential for use of TRV045 in both epilepsy and pain,”
said Carrie Bourdow, President and CEO of Trevena. "We anticipate achieving a range of other milestones in Q3, including new respiratory
data for OLINVYK and receipt of a non-dilutive $15 million tranche from our ex-US royalty based financing. We look forward to updating
you as these developments occur."
Second Quarter 2023 and Recent Corporate
Highlights
| · | Two
TRV045 proof-of-concept studies near completion, exploring the potential for use in epilepsy
and pain. TRV045 is a novel S1P modulator selective for the S1P receptor subtype 1. The
TRV045 Transcranial Magnetic Stimulation (TMS) Study has achieved database lock. The study
is a randomized, double-blind, placebo-controlled, two-way cross-over, multiple dose study
designed to evaluate the pharmacodynamic effects of TRV045 on cortical excitability in healthy
male adults, using both EMG and EEG to measure brain function. The TRV045 Target Engagement
study is a randomized, double-blind, placebo-controlled, four-way cross-over study designed
to build on the nonclinical evidence of anti-inflammatory signaling and a potential disease-modifying
effect of TRV045. |
The Company expects to announce
data from each study in 3Q 2023. Subjects were enrolled at study sites outside of the United States and the studies are not being conducted
under the Investigational New Drug Application (IND) for TRV045.
| · | New
respiratory data from ~200 patient VOLITION real-world outcomes study using continuous respiratory
monitoring expected 3Q 2023. The Company previously reported initial topline GI and delirium
data from the VOLITION study, a real-world, open-label, multi-site study led by clinical
outcomes research experts from Cleveland Clinic and Wake Forest Baptist Health Medical Center.
The respiratory data from the VOLITION study will continue to add to our clinical understanding
of OLINVYK in a real-world setting. |
| · | Previously
announced Electronic Medical Records (EMR) data from the ARTEMIS study. The Company recently
reported data demonstrating OLINVYK-treated patients (n=201) had a statistically significant
~$8,750 (19%) lower cost per admission and ~1.4 day (20%) reduced average length of hospital
stay, compared to matched patients treated with other IV opioids (n=982). There was no statistically
significant difference in the average duration of time in the post-anesthesia care unit (PACU).
The study utilized client and health resource outcomes data from the Cleveland Clinic and
Wake Forest Baptist Health. While an EMR analysis does not provide definitive data regarding
group differences, as seen in a prospectively randomized study, the Company believes the
EMR data bring a unique perspective to understanding how drugs may perform in the real world. |
| · | Previously
announced receipt of $3 million milestone payment for Chinese approval of OLINVYK; Company
anticipates additional $15 million non-dilutive financing tranche in 3Q 2023. The Company
recently reported receipt of a $3 million milestone payment from its partner in China for
the Chinese approval of OLINVYK. Jiangsu Nhwa Pharmaceutical Co. Ltd. (Nhwa) holds an exclusive
license agreement to develop, manufacture, and commercialize OLINVYK in China. The Company
also anticipates the receipt of a $15 million non-dilutive financing tranche in 3Q 2023,
in connection with its ex-US royalty based financing with R-Bridge. |
Financial Results for Second Quarter
2023
For the second quarter of 2023, the
Company reported net revenue of $3.0 million, and a net loss attributable to common stockholders of $8.0 million, or $0.69 per share,
compared to $15.0 million, or $2.26 per share in the second quarter of 2022.
Cash and cash equivalents were $28.1
million as of June 30, 2023, which the Company believes will be sufficient to fund the Company’s operating expenses and capital
expenditure requirements into 2024. This cash balance does not include a $15 million non-dilutive tranche from the R-Bridge Financing
that the Company anticipates receiving in the third quarter of 2023.
About OLINVYK® (oliceridine)
injection
OLINVYK is a new
chemical entity approved by the FDA in August 2020. OLINVYK contains oliceridine, an opioid, which is a Schedule II controlled substance
with a high potential for abuse similar to other opioids. It is indicated in adults for the management of acute pain severe enough to
require an intravenous opioid analgesic and for whom alternative treatments are inadequate. OLINVYK is available in 1 mg/1 mL and 2 mg/2
mL single-dose vials, and a 30 mg/30 mL single-patient-use vial for patient-controlled analgesia (PCA). Approved PCA doses are 0.35 mg
and 0.5 mg and doses greater than 3 mg should not be administered. The cumulative daily dose should not exceed 27 mg. Please see Important
Safety Information, including the BOXED WARNING, and full prescribing information at www.OLINVYK.com.
IMPORTANT
SAFETY INFORMATION
WARNING:
ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; NEONATAL OPIOID WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT
USE WITH BENZODIAZEPINES OR OTHER CENTRAL NERVOUS SYSTEM (CNS) DEPRESSANTS
ADDICTION,
ABUSE, AND MISUSE – OLINVYK exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can
lead to overdose and death. Assess each patient’s risk before prescribing OLINVYK, and monitor all patients regularly for the development
of behaviors or conditions.
LIFE-THREATENING
RESPIRATORY DEPRESSION – Serious, life-threatening, or fatal respiratory depression may occur with use of OLINVYK. Monitor
for respiratory depression, especially during initiation of OLINVYK or following a dose increase.
NEONATAL
OPIOID WITHDRAWAL SYNDROME – Prolonged use of OLINVYK during pregnancy can result in neonatal opioid withdrawal syndrome, which
may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts.
If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome
and ensure that appropriate treatment will be available.
RISK
FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS – Concomitant use of opioids with benzodiazepines or other
CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing
for use in patients for whom alternative treatment options are inadequate; limit dosages and durations to the minimum required; and follow
patients for signs and symptoms of respiratory depression and sedation.
INDICATIONS AND USAGE
OLINVYK is an opioid agonist indicated
in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments
are inadequate.
Limitations of Use
Because of the risks of addiction, abuse,
and misuse with opioids, even at recommended doses, reserve OLINVYK for use in patients for whom alternative treatment options [e.g.,
non-opioid analgesics or opioid combination products]:
| · | Have
not been tolerated, or are not expected to be tolerated |
| · | Have
not provided adequate analgesia, or are not expected to provide adequate analgesia. |
The cumulative total daily dose should
not exceed 27 mg, as total daily doses greater than 27 mg may increase the risk for QTc interval prolongation.
CONTRAINDICATIONS
OLINVYK is contraindicated in patients
with:
| · | Significant
respiratory depression |
| · | Acute
or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment |
| · | Known
or suspected gastrointestinal obstruction, including paralytic ileus |
| · | Known
hypersensitivity to oliceridine (e.g., anaphylaxis) |
WARNINGS AND PRECAUTIONS
| · | OLINVYK
contains oliceridine, a Schedule II controlled substance, that exposes users to the risks of addiction, abuse, and misuse. Although the
risk of addiction in any individual is unknown, it can occur in patients appropriately prescribed OLINVYK. Assess risk, counsel, and
monitor all patients receiving opioids. |
| · | Serious,
life-threatening respiratory depression has been reported with the use of opioids, even when used as recommended, especially in patients
with chronic pulmonary disease, or in elderly, cachectic and debilitated patients. The risk is greatest during initiation of OLINVYK
therapy, following a dose increase, or when used with other drugs that depress respiration. Proper dosing of OLINVYK is essential, especially
when converting patients from another opioid product to avoid overdose. Management of respiratory depression may include close observation,
supportive measures, and use of opioid antagonists, depending on the patient’s clinical status. |
| · | Opioids
can cause sleep-related breathing disorders including central sleep apnea (CSA) and sleep-related hypoxemia with risk increasing in a dose-dependent fashion.
In patients who present with CSA, consider decreasing the dose of opioid using best practices for opioid taper. |
| · | Prolonged
use of opioids during pregnancy can result in withdrawal in the neonate that may be life-threatening. Observe newborns for signs of neonatal
opioid withdrawal syndrome and manage accordingly. Advise pregnant women using OLINVYK for a prolonged period of the risk of neonatal
opioid withdrawal syndrome and ensure that appropriate treatment will be available. |
| · | Profound
sedation, respiratory depression, coma, and death may result from the concomitant use of OLINVYK with benzodiazepines or other CNS depressants
(e.g., non-benzodiazepine sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, other
opioids, or alcohol). Because of these risks, reserve concomitant prescribing of these drugs for use in patients for whom alternative
treatment options are inadequate, prescribe the lowest effective dose, and minimize the duration. |
| · | OLINVYK
was shown to have mild QTc interval prolongation in thorough QT studies where patients were dosed up to 27 mg. Total cumulative
daily doses exceeding 27 mg per day were not studied and may increase the risk for QTc interval prolongation. Therefore, the
cumulative total daily dose of OLINVYK should not exceed 27 mg. |
| · | Increased
plasma concentrations of OLINVYK may occur in patients with decreased Cytochrome P450 (CYP) 2D6 function or normal metabolizers taking
moderate or strong CYP2D6 inhibitors; also in patients taking a moderate or strong CYP3A4 inhibitor, in patients with decreased CYP2D6
function who are also receiving a moderate or strong CYP3A4 inhibitor, or with discontinuation of a CYP3A4 inducer. These patients may
require less frequent dosing and should be closely monitored for respiratory depression and sedation at frequent intervals. Concomitant
use of OLINVYK with CYP3A4 inducers or discontinuation of a moderate or strong CYP3A4 inhibitor can lower the expected concentration,
which may decrease efficacy, and may require supplemental doses. |
| · | Cases
of adrenal insufficiency have been reported with opioid use (usually greater than one month). Presentation and symptoms may be nonspecific
and include nausea, vomiting, anorexia, fatigue, weakness, dizziness, and low blood pressure. If confirmed, treat with physiologic replacement
doses of corticosteroids and wean patient from the opioid. |
| · | OLINVYK
may cause severe hypotension, including orthostatic hypotension and syncope in ambulatory patients. There is increased risk in patients
whose ability to maintain blood pressure has already been compromised by a reduced blood volume or concurrent administration of certain
CNS depressant drugs (e.g., phenothiazines or general anesthetics). Monitor these patients for signs of hypotension. In patients with
circulatory shock, avoid the use of OLINVYK as it may cause vasodilation that can further reduce cardiac output and blood pressure. |
| · | Avoid
the use of OLINVYK in patients with impaired consciousness or coma. OLINVYK should be used with caution in patients who may be susceptible
to the intracranial effects of CO2 retention, such as those with evidence of increased intracranial pressure or brain
tumors, as a reduction in respiratory drive and the resultant CO2 retention can further increase intracranial pressure.
Monitor such patients for signs of sedation and respiratory depression, particularly when initiating therapy. |
| · | As
with all opioids, OLINVYK may cause spasm of the sphincter of Oddi, and may cause increases in serum amylase. Monitor patients with biliary
tract disease, including acute pancreatitis, for worsening symptoms. |
| · | OLINVYK
may increase the frequency of seizures in patients with seizure disorders and may increase the risk of seizures in vulnerable patients.
Monitor patients with a history of seizure disorders for worsened seizure control. |
| · | Do
not abruptly discontinue OLINVYK in a patient physically dependent on opioids. Gradually taper the dosage to avoid a withdrawal syndrome
and return of pain. Avoid the use of mixed agonist/antagonist (e.g., pentazocine, nalbuphine, and butorphanol) or partial agonist (e.g.,
buprenorphine) analgesics in patients who are receiving OLINVYK, as they may reduce the analgesic effect and/or precipitate withdrawal
symptoms. |
| · | OLINVYK
may impair the mental or physical abilities needed to perform potentially hazardous activities such as driving a car or operating machinery. |
| · | Although
self-administration of opioids by patient-controlled analgesia (PCA) may allow each patient to individually titrate to an acceptable
level of analgesia, PCA administration has resulted in adverse outcomes and episodes of respiratory depression. Health care providers
and family members monitoring patients receiving PCA analgesia should be instructed in the need for appropriate monitoring for excessive
sedation, respiratory depression, or other adverse effects of opioid medications. |
ADVERSE REACTIONS
Adverse reactions are described in greater
detail in the Prescribing Information.
The most common (incidence ≥10%)
adverse reactions in Phase 3 controlled clinical trials were nausea, vomiting, dizziness, headache, constipation, pruritus, and hypoxia.
MEDICAL INFORMATION
For medical inquiries or to report an
adverse event, other safety-related information or product complaints for a company product, please contact the Trevena Medical Information
Contact Center at 1-844-465-4686 or email MedInfo@Trevena.com.
You are encouraged to report suspected
adverse events of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Please see Full Prescribing Information,
including Boxed Warning.
About TRV045
TRV045 is a novel,
selective sphingosine-1-phosphate subtype 1 (S1P1) receptor modulator being developed as a potential treatment for acute and
chronic neuropathic pain secondary to diabetic peripheral neuropathy. Through a collaboration with the National Institutes of Health,
Trevena is also exploring TRV045 as a potential treatment for epilepsy.
S1P receptors are
located throughout the body, including the central nervous system, where they are believed to play a role in modulating neurotransmission
and membrane excitability.
Trevena's discovery
efforts have identified a family of compounds that are highly selective for the S1P1 receptor. TRV045 reversed thermal hyperalgesia,
a measure of neuropathic pain, in nonclinical models of diabetic peripheral neuropathy and chemotherapy-induced peripheral neuropathy.
TRV045 was not associated with lymphopenia and produced no changes in blood pressure, heart rate, or respiratory function at or above
pharmacologically active doses in nonclinical studies. TRV045 is an investigational product and is not yet approved by the FDA.
About Trevena
Trevena, Inc. is a biopharmaceutical
company focused on the development and commercialization of innovative medicines for patients with CNS disorders. The Company has one
approved product in the United States, OLINVYK® (oliceridine) injection, indicated in adults for the management of
acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Company’s
novel pipeline is based on Nobel Prize winning research and includes three differentiated investigational drug candidates: TRV045 for
diabetic neuropathic pain and epilepsy, TRV250 for the acute treatment of migraine and TRV734 for maintenance treatment of opioid use
disorder.
For more information, please visit www.Trevena.com
Forward-Looking
Statements
Any statements
in this press release about future expectations, plans and prospects for the Company, including statements about the Company’s
strategy, future operations, clinical development and trials of its therapeutic candidates, plans for potential future product candidates
and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,”
“intend,” “may,” “plan,” “predict,” “project,” “suggest,” “target,”
“potential,” “will,” “would,” “could,” “should,” “continue,”
and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of
1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors,
including: the status, timing, costs, results and interpretation of the Company’s clinical trials or any future trials of any of
the Company’s investigational drug candidates; the uncertainties inherent in conducting clinical trials; expectations for regulatory
interactions, submissions and approvals, including the Company’s assessment of discussions with FDA; available funding; uncertainties
related to the Company’s intellectual property; other matters that could affect the availability or commercial potential of the
Company’s therapeutic candidates and approved product; and other factors discussed in the Risk Factors set forth in the Company’s
Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission (SEC) and in other filings
the Company makes with the SEC from time to time. In addition, the forward-looking statements included in this press release represent
the Company’s views only as of the date hereof. The Company anticipates that subsequent events and developments may cause the Company’s
views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, it specifically
disclaims any obligation to do so, except as may be required by law.
For more information,
please contact:
Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors,
LLC
daniel@lifesciadvisors.com
(617) 430-7576
Company Contact:
Bob Yoder
SVP and Chief Business
Officer
Trevena, Inc.
(610) 354-8840
TREVENA, INC.
Condensed Statements of Operations
(Unaudited, in thousands except share and per share data)
| |
Three Months Ended Jun 30, | | |
Six Months Ended Jun 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
Product revenue | |
$ | 21 | | |
$ | - | | |
$ | 27 | | |
$ | - | |
License revenue | |
| 3,000 | | |
| - | | |
| 3,000 | | |
| 20 | |
Total revenue | |
| 3,021 | | |
| - | | |
| 3,027 | | |
| 20 | |
| |
| | | |
| | | |
| | | |
| | |
Operating expenses: | |
| | | |
| | | |
| | | |
| | |
Cost of goods sold | |
| 88 | | |
| 216 | | |
| 214 | | |
| 423 | |
Selling, general and administrative | |
| 5,138 | | |
| 10,306 | | |
| 11,227 | | |
| 21,320 | |
Research and development | |
| 3,991 | | |
| 4,291 | | |
| 7,900 | | |
| 9,550 | |
Total operating expenses | |
| 9,217 | | |
| 14,813 | | |
| 19,341 | | |
| 31,293 | |
Loss from operations | |
| (6,196 | ) | |
| (14,813 | ) | |
| (16,314 | ) | |
| (31,273 | ) |
Other income | |
| (1,816 | ) | |
| (168 | ) | |
| 483 | | |
| (97 | ) |
Net loss | |
$ | (8,012 | ) | |
$ | (14,981 | ) | |
$ | (15,831 | ) | |
$ | (31,370 | ) |
| |
| | | |
| | | |
| | | |
| | |
Per share information: | |
| | | |
| | | |
| | | |
| | |
Net loss per share of common stock, basic and diluted | |
$ | (0.69 | ) | |
$ | (2.26 | ) | |
$ | (1.49 | ) | |
$ | (4.74 | ) |
Weighted average shares outstanding, basic and diluted | |
| 11,580,128 | | |
| 6,621,083 | | |
| 10,592,586 | | |
| 6,620,942 | |
TREVENA, INC.
Condensed Balance Sheets
(Unaudited, in thousands)
| |
June 30, 2023 | | |
December 31, 2022 | |
Assets | |
| | |
| |
Current assets: | |
| | | |
| | |
Cash and cash equivalents | |
$ | 28,097 | | |
$ | 38,320 | |
Inventories | |
| 901 | | |
| 906 | |
Prepaid expenses and other current assets | |
| 3,972 | | |
| 1,782 | |
Total current assets | |
| 32,970 | | |
| 41,008 | |
Restricted cash | |
| 540 | | |
| 1,960 | |
Property and equipment, net | |
| 1,343 | | |
| 1,488 | |
Right-of-use lease assets | |
| 3,955 | | |
| 4,224 | |
Other assets | |
| 51 | | |
| - | |
Total assets | |
$ | 38,859 | | |
$ | 48,680 | |
| |
| | | |
| | |
Liabilities and stockholders’ equity | |
| | | |
| | |
Current liabilities: | |
| | | |
| | |
Accounts payable, net | |
$ | 2,527 | | |
$ | 2,372 | |
Accrued expenses and other current liabilities | |
| 4,695 | | |
| 5,461 | |
Current portion of lease liabilities | |
| 954 | | |
| 899 | |
Total current liabilities | |
| 8,176 | | |
| 8,732 | |
Loans payable, net | |
| 14,176 | | |
| 13,430 | |
Leases, net of current portion | |
| 4,946 | | |
| 5,436 | |
Warrant liability | |
| 1,779 | | |
| 5,483 | |
Total liabilities | |
| 29,077 | | |
| 33,081 | |
| |
| | | |
| | |
Common stock | |
| 14 | | |
| 8 | |
Additional paid-in capital | |
| 573,371 | | |
| 563,362 | |
Accumulated deficit | |
| (563,603 | ) | |
| (547,772 | ) |
Accumulated other comprehensive income (loss) | |
| - | | |
| 1 | |
Total stockholders’ equity | |
| 9,782 | | |
| 15,599 | |
Total liabilities and stockholders’ equity | |
$ | 38,859 | | |
$ | 48,680 | |
v3.23.2
Cover
|
Aug. 14, 2023 |
Cover [Abstract] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Aug. 14, 2023
|
Entity File Number |
001-36193
|
Entity Registrant Name |
TREVENA, INC.
|
Entity Central Index Key |
0001429560
|
Entity Tax Identification Number |
26-1469215
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
955 Chesterbrook Boulevard
|
Entity Address, Address Line Two |
Suite 110
|
Entity Address, City or Town |
Chesterbrook
|
Entity Address, State or Province |
PA
|
Entity Address, Postal Zip Code |
19087
|
City Area Code |
610
|
Local Phone Number |
354-8840
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Title of 12(b) Security |
Common Stock, $0.001 par value
|
Trading Symbol |
TRVN
|
Security Exchange Name |
NASDAQ
|
Entity Emerging Growth Company |
false
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Trevena (NASDAQ:TRVN)
Historical Stock Chart
From May 2024 to Jun 2024
Trevena (NASDAQ:TRVN)
Historical Stock Chart
From Jun 2023 to Jun 2024